Welcome to our dedicated page for Assertio Holdings SEC filings (Ticker: ASRT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Drug royalty expirations, patent litigation, and acquisition earn-outs make Assertio Holdings Inc. (ASRT) filings more than financial paperwork—they are roadmaps to how CAMBIA, Gralise, Zipsor and new oncology asset Rolvedon protect revenue in a competitive market. Yet combing through hundreds of pages to find those details is a challenge many investors voice when searching “Assertio SEC filings explained simply” or “how to decode an Assertio annual report 10-K”.
Stock Titan solves that problem. Our AI-powered summaries translate complex disclosures into clear language, flagging where the Assertio annual report 10-K simplified discusses patent cliffs, where the Assertio quarterly earnings report 10-Q filing updates product sales, and how the latest Assertio 8-K material events explained could shift valuation. Real-time alerts track Assertio Form 4 insider transactions real-time, so you instantly spot Assertio executive stock transactions Form 4. Whether you need a quick take or full text, every filing—10-K, 10-Q, 8-K, S-3, DEF 14A—arrives the moment EDGAR posts it.
Use the platform to:
- Monitor Assertio insider trading Form 4 transactions before material announcements.
- Run Assertio earnings report filing analysis without manual number crunching.
- Review the Assertio proxy statement executive compensation section to compare pay with performance.
- Track clinical milestones and licensing deals through each 8-K.
No more digging through dense footnotes—understanding Assertio SEC documents with AI means you spend time making decisions, not searching for data.
Assertio Holdings (ASRT) reported lower revenue and wider losses for the quarter and first half of 2025 while taking strategic steps to simplify the business. Total revenues were $29.2 million for the three months and $55.7 million for the six months ended June 30, 2025, down from $31.1 million and $63.6 million a year earlier, respectively, driven by lower INDOCIN sales despite higher ROLVEDON sales of $16.1 million in the quarter. Cost pressures included higher amortization of intangibles of $9.2 million in the quarter.
The company recorded a net loss of $16.4 million ($0.17 per share) for the quarter and $29.9 million ($0.31 per share) for the six months, which includes an $8.2 million loss on the divestiture of Assertio Therapeutics. Total assets declined to $273.8 million and shareholders' equity fell to $93.3 million. Cash and cash equivalents were $47.1 million with short-term investments of $51.1 million.
Material operational items: the Therapeutics divestiture removed Assertio from opioid-related litigation exposure but produced an $8.2 million loss; the company ceased commercialization of Otrexup (incurring $3.8 million of related costs); management recorded a $16.0 million accrual related to the Luo settlement with corresponding insurance recoverable that was later settled and reduced to zero. The company maintains $39.0 million of 6.5% convertible notes due 2027 and a full valuation allowance on deferred tax assets.
FAQ
What is the current stock price of Assertio Holdings (ASRT)?
What is the market cap of Assertio Holdings (ASRT)?
